# A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART

> **NCT02454556** · PHASE3 · COMPLETED · sponsor: **Gema Biotech S.A.** · enrollment: 106 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** FOLITIME®
- **DRUG:** Gonal-F®

## Key facts

- **NCT ID:** NCT02454556
- **Lead sponsor:** Gema Biotech S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2017-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02454556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02454556, "A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02454556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*